Ulodesine

Drug Profile

Ulodesine

Alternative Names: BCX-4208; R3421; RO5092888; Ulodesine succinate

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Albert Einstein College of Medicine; Industrial Research Limited
  • Developer BioCryst Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antipsoriatics; Pyrimidinones; Pyrrolidines
  • Mechanism of Action Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gout
  • Discontinued Plaque psoriasis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Jun 2015 Ulodesine is still in phase II development for Gout in USA
  • 30 Jun 2015 Ulodesine is still available for licensing as of 30 Jun 2015. http://www.biocryst.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top